Daijiro Tomii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Daijiro Tomii has a total of 345 co-authors. Here are the top co-authors by number of shared publications:
Stephan Windecker
29 shared publications- Thomas Pilgrim
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
27 shared publications Jonas Lanz
26 shared publicationsDavid Reineke
20 shared publications- Stefan Stortecky
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
15 shared publications Masaaki Nakase
14 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (21) , 2857-2871
Prosthesis–Patient Mismatch and Patient-Centered Outcomes After TAVR
- 9 November 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (21) , 2857-2871
Open AccessProsthesis–Patient Mismatch and Patient-Centered Outcomes After TAVR
- Open Access
- 7 November 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 72
Guideline-directed medical therapy use, persistence, and cardiovascular outcomes following ST-segment elevation myocardial infarction: a pooled analysis of three randomised trials with external registry validation
- 7 November 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 72
Open AccessGuideline-directed medical therapy use, persistence, and cardiovascular outcomes following ST-segment elevation myocardial infarction: a pooled analysis of three randomised trials with external registry validation
- Open Access
- 28 September 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (18) , 2518-2521
Acute Management of Periprocedural Stroke Following Transcatheter Aortic Valve Replacement
- 28 September 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (18) , 2518-2521
Open AccessAcute Management of Periprocedural Stroke Following Transcatheter Aortic Valve Replacement
- Open Access
- 28 August 2026
- Published by Elsevier in The Lancet Digital Health
- Vol. 8 (9)
Multimodal artificial intelligence-based long-term mortality prediction after transcatheter aortic valve implantation: a multicentre development, validation, and testing study
- 28 August 2026
- Published by Elsevier in The Lancet Digital Health
- Vol. 8 (9)
Open AccessMultimodal artificial intelligence-based long-term mortality prediction after transcatheter aortic valve implantation: a multicentre development, validation, and testing study
- Open Access
- 28 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Sex-Specific Differences in Patient-Centered Outcomes After Transcatheter Aortic Valve Replacement
- 28 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (10)
Open AccessSex-Specific Differences in Patient-Centered Outcomes After Transcatheter Aortic Valve Replacement
- Open Access
- 26 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8)
Optimized Balloon-Expandable Transcatheter Aortic Valve Implantation and Clinical Outcomes
- 26 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (8)
Open AccessOptimized Balloon-Expandable Transcatheter Aortic Valve Implantation and Clinical Outcomes
- Open Access
- 1 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004221
Complete versus incomplete coronary revascularisation in patients undergoing PCI after TAVI
Background: The optimal revascularisation strategy for patients undergoing percutaneous coronary intervention (PCI) after transcatheter aortic valve implantation (TAVI) remains undefined. In particular, the prognostic impact of complete revascularisation (CR) versus incomplete revascularisation (ICR) in this setting is unknown. Aims: To evaluate the long-term clinical outcomes of CR versus ICR in patients undergoing PCI after TAVI. Methods: We analysed 447 patients from the multicentre, international Revascularization After Transcatheter Aortic Valve Implantation (REVIVAL) registry who underwent PCI after TAVI between 2008 and 2023. Patients were classified as CR or ICR according to the presence of residual significant stenosis following PCI. The primary endpoint was the 4-year incidence of major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction or stroke. The Kaplan-Meier method was used to estimate cumulative event rates, and a weighted Cox regression model employing an entropy balance approach was used to adjust for possible confounders. Results: ICR was achieved in 132 patients (29.5%) and CR in 315 patients (70.5%). The mean follow-up after PCI was 1065±904 days (1213±938 in the ICR group; 1002±883 in the CR group). The crude 4-year incidence of MACE was 35.0% with ICR and 34.7% with CR (HR 0.93, 95% CI 0.62 to 1.39, p=0.710). Adjusted analysis confirmed no significant difference (32.5% vs 34.1%; HR 1.01, 95% CI 0.62 to 1.64, p=0.971). Conclusion: In this registry, CR after TAVI was common but not associated with improved outcomes compared with ICR. These results support a selective rather than systematic pursuit of CR in elderly, high-risk post-TAVI patients.
- 1 July 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004221
Open AccessComplete versus incomplete coronary revascularisation in patients undergoing PCI after TAVI
Background: The optimal revascularisation strategy for patients undergoing percutaneous coronary intervention (PCI) after transcatheter aortic valve implantation (TAVI) remains undefined. In particular, the prognostic impact of complete revascularisation (CR) versus incomplete revascularisation (ICR) in this setting is unknown. Aims: To evaluate the long-term clinical outcomes of CR versus ICR in patients undergoing PCI after TAVI. Methods: We analysed 447 patients from the multicentre, international Revascularization After Transcatheter Aortic Valve Implantation (REVIVAL) registry who underwent PCI after TAVI between 2008 and 2023. Patients were classified as CR or ICR according to the presence of residual significant stenosis following PCI. The primary endpoint was the 4-year incidence of major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction or stroke. The Kaplan-Meier method was used to estimate cumulative event rates, and a weighted Cox regression model employing an entropy balance approach was used to adjust for possible confounders. Results: ICR was achieved in 132 patients (29.5%) and CR in 315 patients (70.5%). The mean follow-up after PCI was 1065±904 days (1213±938 in the ICR group; 1002±883 in the CR group). The crude 4-year incidence of MACE was 35.0% with ICR and 34.7% with CR (HR 0.93, 95% CI 0.62 to 1.39, p=0.710). Adjusted analysis confirmed no significant difference (32.5% vs 34.1%; HR 1.01, 95% CI 0.62 to 1.64, p=0.971). Conclusion: In this registry, CR after TAVI was common but not associated with improved outcomes compared with ICR. These results support a selective rather than systematic pursuit of CR in elderly, high-risk post-TAVI patients.
- Open Access
- 26 May 2026
- Published by Elsevier in American Heart Journal
- Vol. 300, 107495
Relationship between baseline patient-reported health status and patient-centered outcomes after transcatheter aortic valve replacement
- 26 May 2026
- Published by Elsevier in American Heart Journal
- Vol. 300, 107495
Open AccessRelationship between baseline patient-reported health status and patient-centered outcomes after transcatheter aortic valve replacement
- Open Access
- 20 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (7) , e015770
Clinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation
BACKGROUND: The best management of coronary artery disease in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) is debated. We investigated the clinical impact of the residual extent of myocardium at risk in patients undergoing TAVI. METHODS: Patients enrolled in the REVASC-TAVI (Management of Myocardial Revascularization in Patients Undergoing TAVI With Coronary Artery Disease) international multicenter registry were stratified according to the myocardium jeopardized by coronary artery disease using the British Cardiovascular Intervention Society Jeopardy Score (BCIS-JS) after a planned coronary revascularization. A planned revascularization included percutaneous coronary interventions performed before TAVI, during TAVI, or within 1 month after TAVI. The study population was divided according to the residual BCIS-JS (rBCIS-JS): patients with extensive residual myocardial at risk (rBCIS-JS >4 group) and patients without extensive residual myocardial at risk (rBCIS-JS ≤4 group). The primary study end point was the composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and rehospitalization for heart failure at 2 years. RESULTS: Among the 2407 patients enrolled, 294 pairs of patients were selected by propensity matching and compared. At 2-year follow-up, the incidence of the primary end point was higher in patients with rBCIS-JS >4 compared with patients with rBCIS-JS ≤4 (37.5% versus 23.0%, P =0.004). A significantly lower rate of myocardial infarction was reported in patients with BCIS-JS ≤4 (8.2% versus 2.6%, P =0.011). At multivariate analysis, rBCIS-JS >4 (hazard ratio, 1.43 [95% CI, 1.11–1.84]; P =0.005) independently predicted 2-year major adverse cardiac and cerebrovascular events. CONCLUSIONS: In patients with concomitant coronary artery disease and severe aortic stenosis, the residual myocardial risk significantly affects TAVI outcomes. In particular, a rBCIS-JS >4 is associated with higher rates of major adverse cardiac and cerebrovascular events at 2 years.
- 20 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (7) , e015770
Open AccessClinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation
BACKGROUND: The best management of coronary artery disease in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) is debated. We investigated the clinical impact of the residual extent of myocardium at risk in patients undergoing TAVI. METHODS: Patients enrolled in the REVASC-TAVI (Management of Myocardial Revascularization in Patients Undergoing TAVI With Coronary Artery Disease) international multicenter registry were stratified according to the myocardium jeopardized by coronary artery disease using the British Cardiovascular Intervention Society Jeopardy Score (BCIS-JS) after a planned coronary revascularization. A planned revascularization included percutaneous coronary interventions performed before TAVI, during TAVI, or within 1 month after TAVI. The study population was divided according to the residual BCIS-JS (rBCIS-JS): patients with extensive residual myocardial at risk (rBCIS-JS >4 group) and patients without extensive residual myocardial at risk (rBCIS-JS ≤4 group). The primary study end point was the composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, and rehospitalization for heart failure at 2 years. RESULTS: Among the 2407 patients enrolled, 294 pairs of patients were selected by propensity matching and compared. At 2-year follow-up, the incidence of the primary end point was higher in patients with rBCIS-JS >4 compared with patients with rBCIS-JS ≤4 (37.5% versus 23.0%, P =0.004). A significantly lower rate of myocardial infarction was reported in patients with BCIS-JS ≤4 (8.2% versus 2.6%, P =0.011). At multivariate analysis, rBCIS-JS >4 (hazard ratio, 1.43 [95% CI, 1.11–1.84]; P =0.005) independently predicted 2-year major adverse cardiac and cerebrovascular events. CONCLUSIONS: In patients with concomitant coronary artery disease and severe aortic stenosis, the residual myocardial risk significantly affects TAVI outcomes. In particular, a rBCIS-JS >4 is associated with higher rates of major adverse cardiac and cerebrovascular events at 2 years.
- 13 April 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (7) , 871-873
The Gradient Paradox After Transcatheter Mitral Valve-in-Valve Implantation
- 13 April 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (7) , 871-873
The Gradient Paradox After Transcatheter Mitral Valve-in-Valve Implantation